These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 19635156)

  • 1. Mycophenolate pharmacokinetics and pharmacodynamics in belatacept treated renal allograft recipients - a pilot study.
    Bremer S; Vethe NT; Rootwelt H; Jørgensen PF; Stenstrøm J; Holdaas H; Midtvedt K; Bergan S
    J Transl Med; 2009 Jul; 7():64. PubMed ID: 19635156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and pharmacodynamics of mycophenolic acid in stable renal transplant recipients treated with low doses of mycophenolate mofetil.
    Brunet M; Martorell J; Oppenheimer F; Vilardell J; Millán O; Carrillo M; Rojo I; Corbella J
    Transpl Int; 2000; 13 Suppl 1():S301-5. PubMed ID: 11112019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression in renal transplant recipients.
    Langman LJ; LeGatt DF; Halloran PF; Yatscoff RW
    Transplantation; 1996 Sep; 62(5):666-72. PubMed ID: 8830834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of IMPDH1 is regulated in response to mycophenolate concentration.
    Bremer S; Vethe NT; Rootwelt H; Bergan S
    Int Immunopharmacol; 2009 Feb; 9(2):173-80. PubMed ID: 19010451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamics of intensified versus standard dosing of mycophenolate sodium in renal transplant patients.
    Glander P; Sommerer C; Arns W; Ariatabar T; Kramer S; Vogel EM; Shipkova M; Fischer W; Zeier M; Budde K
    Clin J Am Soc Nephrol; 2010 Mar; 5(3):503-11. PubMed ID: 20150450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inosine monophosphate dehydrogenase (IMPDH) activity as a pharmacodynamic biomarker of mycophenolic acid effects in pediatric kidney transplant recipients.
    Fukuda T; Goebel J; Thøgersen H; Maseck D; Cox S; Logan B; Sherbotie J; Seikaly M; Vinks AA
    J Clin Pharmacol; 2011 Mar; 51(3):309-20. PubMed ID: 20418509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic and pharmacodynamic analysis of enteric-coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patients.
    Sommerer C; Müller-Krebs S; Schaier M; Glander P; Budde K; Schwenger V; Mikus G; Zeier M
    Br J Clin Pharmacol; 2010 Apr; 69(4):346-57. PubMed ID: 20406219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of IMPDH1 and IMPDH2 after transplantation and initiation of immunosuppression.
    Bremer S; Mandla R; Vethe NT; Rasmussen I; Rootwelt H; Line PD; Midtvedt K; Bergan S
    Transplantation; 2008 Jan; 85(1):55-61. PubMed ID: 18192912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamics of mycophenolic acid in CD4+ cells: a single-dose study of IMPDH and purine nucleotide responses in healthy individuals.
    Vethe NT; Bremer S; Rootwelt H; Bergan S
    Ther Drug Monit; 2008 Dec; 30(6):647-55. PubMed ID: 18806697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetic-pharmacodynamic modelling of mycophenolic acid in paediatric renal transplant recipients in the early post-transplant period.
    Dong M; Fukuda T; Cox S; de Vries MT; Hooper DK; Goebel J; Vinks AA
    Br J Clin Pharmacol; 2014 Nov; 78(5):1102-12. PubMed ID: 24837828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inosine monophosphate dehydrogenase activity in renal allograft recipients during mycophenolate treatment.
    Vethe NT; Mandla R; Line PD; Midtvedt K; Hartmann A; Bergan S
    Scand J Clin Lab Invest; 2006; 66(1):31-44. PubMed ID: 16464785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: a prospective study in 100 de novo renal allograft recipients.
    Kuypers DR; Claes K; Evenepoel P; Maes B; Coosemans W; Pirenne J; Vanrenterghem Y
    J Clin Pharmacol; 2003 Aug; 43(8):866-80. PubMed ID: 12953344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pharmacokinetics and pharmacodynamics of mycophenolate mofetil in younger and elderly renal transplant recipients.
    Tang JT; de Winter BC; Hesselink DA; Sombogaard F; Wang LL; van Gelder T
    Br J Clin Pharmacol; 2017 Apr; 83(4):812-822. PubMed ID: 27753146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of IMPDH1 gene polymorphisms with subclinical acute rejection and mycophenolic acid exposure parameters on day 28 after renal transplantation.
    Kagaya H; Miura M; Saito M; Habuchi T; Satoh S
    Basic Clin Pharmacol Toxicol; 2010 Aug; 107(2):631-6. PubMed ID: 20136638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inosine monophosphate dehydrogenase activity and mycophenolate pharmacokinetics in children with nephrotic syndrome treated with mycophenolate mofetil.
    Sobiak J; Resztak M; Zachwieja J; Ostalska-Nowicka D
    Clin Exp Pharmacol Physiol; 2022 Nov; 49(11):1197-1208. PubMed ID: 35877984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inosine monophosphate dehydrogenase activity in paediatrics: age-related regulation and response to mycophenolic acid.
    Rother A; Glander P; Vitt E; Czock D; von Ahsen N; Armstrong VW; Oellerich M; Budde K; Feneberg R; Tönshoff B; Weber LT
    Eur J Clin Pharmacol; 2012 Jun; 68(6):913-22. PubMed ID: 22274404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of inosine monophosphate dehydrogenase activity in human CD4+ cells isolated from whole blood during mycophenolic acid therapy.
    Vethe NT; Bergan S
    Ther Drug Monit; 2006 Oct; 28(5):608-13. PubMed ID: 17038874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients.
    Kato Y; Tojimbara T; Iwadoh K; Koyama I; Nanmoku K; Kai K; Sannomiya A; Nakajima I; Fuchinoue S; Teraoka S
    Int Immunopharmacol; 2006 Dec; 6(13-14):1984-92. PubMed ID: 17161352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inosine monophosphate dehydrogenase variability in renal transplant patients on long-term mycophenolate mofetil therapy.
    Chiarelli LR; Molinaro M; Libetta C; Tinelli C; Cosmai L; Valentini G; Dal Canton A; Regazzi M
    Br J Clin Pharmacol; 2010 Jan; 69(1):38-50. PubMed ID: 20078611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inosine 5'-Monophosphate Dehydrogenase Activity for the Longitudinal Monitoring of Mycophenolic Acid Treatment in Kidney Allograft Recipients.
    Glander P; Waiser J; Hambach P; Bachmann F; Budde K; Eckardt KU; Friedersdorff F; Gaedeke J; Kron S; Lorkowski C; Mai M; Neumayer HH; Peters R; Rudolph B; Schmidt D; Wu K; Liefeldt L
    Transplantation; 2021 Apr; 105(4):916-927. PubMed ID: 32496356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.